. 2021 Oct 9;9(10):1421. doi: 10.3390/biomedicines9101421

Table 1.

Monoclonal antibodies shown to protect mice in bubonic plague models (subcutaneous challenge with bacteria).

Antigen ^a	mAb Description	Antibody/Therapeutic Administration			Y. pestis Challenge Strain ^d	Challenge Dose (LD₅₀)	Ref.
Antigen ^a	mAb Description	Route	Concentration	Schedule	Y. pestis Challenge Strain ^d	Challenge Dose (LD₅₀)	Ref.
F1; LcrV; F1V + LcrV	human IgG1	IP	500 µg	24 h pre–120 h post	CO92	25–40	202
LcrV	mouse	IP	350 µg	24 h pre	GB	12	156
LcrV ^b	mouse IgG1, IgG2a	IP	1–500 µg	24 h pre	CO92 or C12	21–39	192
LcrV; F1 + LcrV	mouse IgG1	IP	0.7–100 µg	4 h pre–96 post	GB	9.6–91,000	200
LcrV	mouse IgG1	IP	200 µg	1 h pre	CO92	20	191
F1 ^c	mouse IgG1	IP	125–500 µg	6 h or 24 h pre	CO92	48–54	199
F1	not reported	IV	100 µg	24 h pre	141	600	203

a, unless otherwise noted mAbs tested in BALB/c female mice; b, tested in BALB/c and Swiss Webster mice; c, tested in Swiss Webster female mice; d, bacteria delivered via subcutaneous injection.